Personalized Risk Stratification with Diagnostic and Prognostic Relevance for Heart Failure: New Perspectives and Challenges
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: 20 November 2024 | Viewed by 45
Special Issue Editor
Interests: cardiovascular medicine; medical statistics
Special Issue Information
Dear Colleagues,
Heart failure (HF) remains a pressing global health concern with significant morbidity, mortality, and economic burden. Over the years, advancements in the understanding of HF pathophysiology and management have led to the emergence of personalized risk stratification approaches with diagnostic and prognostic relevance. This Special Issue aims at exploring the latest perspectives and challenges in personalized risk stratification for HF, highlighting new research avenues and clinical implications.
Historically, risk stratification in HF has evolved from traditional clinical predictors to incorporating novel biomarkers, imaging modalities, and genomic markers. The integration of multi-omics data, artificial intelligence, and machine learning algorithms has enabled more precise risk prediction tailored to individual patients. Despite these advances, challenges such as data integration, validation, and implementation in clinical practice persist.
This Special Issue seeks to gather cutting-edge research on innovative risk stratification methods, including but not limited to novel biomarkers, advanced imaging techniques, genetic profiling, and digital health technologies. Additionally, it aims at providing a platform for discussing the translation of research findings into clinical practice and the potential impact on patient outcomes and healthcare resource utilization. Through collaborative efforts, this Special Issue aims at advancing the field of personalized risk stratification in HF and improving patient care.
Original research articles, review articles, and short communications are invited.
Dr. Dimitrios V. Moysidis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart failure
- cardiovascular prevention
- risk stratification
- cardiovascular pathology
- diagnostic modalities
- treatment targets
